Delivery Order 75A50122D00004-75A50123F61007

This is a firm fixed-price delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Seqirus Inc., a division of global biotechnology company CSL Seqirus. The $28,528,623.00 contract is for the acquisition of bulk influenza A/Astrakhan/3212/2020 (H5N8) antigen and the formulation and filling of the antigen into final containers. Seqirus operates a manufacturing facility in Holly Springs, North Carolina and is a leading provider of medical countermeasures for pandemic preparedness and response to the U.S. federal government. This contract is part of a larger $13.4 billion Indefinite Delivery Contract (IDC) awarded to Seqirus in February 2022, which serves as the primary vehicle for the company's federal contracting activities with HHS ASPR. No set-aside designation was used for this award.